What is the recommended management for a patient with CREST syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia)?

Management of CREST Syndrome

Patients with CREST syndrome require organ-specific treatment guided by the 2017 EULAR recommendations, with calcium channel blockers (nifedipine) as first-line therapy for Raynaud's phenomenon, proton pump inhibitors for esophageal dysmotility, and no proven medical therapy for calcinosis—making early screening for life-threatening complications (pulmonary arterial hypertension and interstitial lung disease) the most critical initial step. 1, 2

Initial Screening and Risk Stratification

All patients must undergo baseline screening for pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) using pulmonary function tests, high-resolution CT, and echocardiography, as these complications determine mortality. 2 While ILD occurs in 40-75% of systemic sclerosis patients, only 15-18% have progressive disease requiring treatment, making screening essential for identifying high-risk individuals. 2

Regular blood pressure monitoring is mandatory, particularly in patients with anti-RNA polymerase III antibodies, to detect scleroderma renal crisis early. 2 This complication requires immediate intervention and can be fatal if missed.

Raynaud's Phenomenon Management

Start with dihydropyridine calcium channel blockers (specifically nifedipine) as first-line pharmacological therapy. 1, 2, 3 This recommendation is based on meta-analyses showing nifedipine reduces both frequency and severity of attacks in approximately two-thirds of patients. 3

If calcium channel blockers provide inadequate response, add or switch to PDE-5 inhibitors (sildenafil or tadalafil). 1, 2, 3 These agents effectively reduce attack frequency, duration, and severity, and have the added benefit of treating digital ulcers if present. 3

For severe Raynaud's phenomenon unresponsive to oral therapies, use intravenous iloprost. 1, 2, 3 This prostacyclin analogue is particularly effective for severe, refractory cases. 3

Non-pharmacological measures

• Avoid cold exposure, trauma, stress, smoking, and vibration injury 3
• Use proper warm clothing including mittens (not gloves), insulated footwear, and hand/foot warmers 3
• Consider physical therapy to stimulate blood flow 3

Digital Ulcer Management

For active digital ulcers, use PDE-5 inhibitors and/or intravenous iloprost for healing. 1, 2, 3 Both agents have proven efficacy in promoting ulcer healing. 3

For prevention of new digital ulcers (not healing existing ones), use bosentan, particularly in patients with multiple (≥4) digital ulcers at baseline. 1, 2, 3 This endothelin receptor antagonist specifically reduces new ulcer formation but does not improve healing of existing ulcers. 3

In refractory cases with persistent ulcers despite medical therapy, consider digital sympathectomy, botulinum toxin infiltrations, or fat grafting. 3, 4 One case report demonstrated dramatic improvement with botulinum toxin (20 units total) showing over 50% pain reduction within one week and ulcer healing within three weeks. 4

Esophageal Dysmotility Management

Use proton pump inhibitors for gastroesophageal reflux disease to prevent esophageal ulcers and strictures. 1, 2 This is critical as esophageal complications are nearly universal in CREST syndrome. 5

Add prokinetic drugs for symptomatic motility disturbances. 1, 2

Monitor nutritional status aggressively, as malnutrition from gastrointestinal involvement is a leading cause of mortality. 2 This is a commonly overlooked but critical aspect of management. 2

Sclerodactyly and Skin Fibrosis Management

For patients with early disease (within 2-5 years of first non-Raynaud's features) and significant skin involvement, use methotrexate, mycophenolate mofetil, or rituximab. 1, 2 Treatment is most effective during this early inflammatory window. 2

Consider tocilizumab for early, inflammatory diffuse cutaneous disease. 1, 2

Calcinosis Management

There is no proven medical therapy for calcinosis—surgical excision should be considered early for symptomatic lesions rather than prolonged ineffective medical management. 2, 6 One case series demonstrated successful complete resection of large tumoral calcinosis masses with good functional outcomes and no recurrence at 6 months. 6

Do not waste time with unproven medical therapies when calcinosis causes pain or functional impairment—refer for surgical evaluation. 2, 6

Interstitial Lung Disease Management

Use mycophenolate mofetil as first-line therapy for ILD. 2 This is the preferred agent based on current evidence. 2

Cyclophosphamide or rituximab are acceptable alternatives for first-line treatment. 2

For progressive fibrotic ILD, add nintedanib alone or in combination with mycophenolate mofetil. 2

Pulmonary Arterial Hypertension Management

Start combination therapy with PDE-5 inhibitors and endothelin receptor antagonists as first-line treatment for PAH. 2 This differs from sequential monotherapy approaches. 2

For advanced PAH (WHO functional class III and IV), use intravenous epoprostenol. 2

Do NOT use anticoagulants (warfarin) for SSc-PAH—this differs critically from idiopathic PAH management and is not supported by evidence. 2 This is a common pitfall to avoid. 2

Other prostacyclin analogues or riociguat can be considered as alternatives. 1, 2

Scleroderma Renal Crisis Management

Use ACE inhibitors immediately at diagnosis of scleroderma renal crisis. 2 This is a medical emergency requiring prompt intervention. 2

Monitor blood pressure regularly in patients on glucocorticoids, as they have increased risk of renal crisis. 2

Critical Pitfalls to Avoid

• Do not delay screening for ILD and PAH—these complications determine mortality and early intervention changes natural history 2
• Do not use anticoagulation routinely for SSc-PAH as you would for idiopathic PAH 2
• Do not assume typical disease progression—many patients with diffuse disease do not improve after 4 years and may worsen later 2
• Do not overlook nutritional status—malnutrition from GI involvement is a leading cause of mortality 2
• Do not pursue prolonged ineffective medical management for symptomatic calcinosis—refer for surgical evaluation early 2, 6
• Ensure early rheumatology referral for optimal outcomes, as rheumatologists diagnose earlier and prescribe disease-modifying therapies more frequently 3